Company profile
BLACK DIAMOND THERAPEUTICS, INC.
NASDAQ:BDTXBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| TUXOBERTINIB | phase1 | — | 1 | terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04209465 | phase1 | terminated | 2019-12-19 | 2022-09-02 | Black Diamond Therapeutics, Inc. | A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors. |
| NCT05256290 | phase1_2 | active_not_recruiting | 2022-03-31 | 2025-11-03 | Black Diamond Therapeutics, Inc. | Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations |
| NCT07326566 | phase2 | recruiting | 2026-05-05 | 2028-11-01 | Black Diamond Therapeutics, Inc. | Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII |
FDA applications (0)
No records yet.